Artelo Biosciences Inc (ARTL)

Artelo Biosciences experienced several stock events in the past six months. These include business updates, financial results, the appointment of a new CFO, publication of peer-reviewed articles, a delisting determination from Nasdaq, a favorable decision from a Nasdaq Hearing Panel, and a significant stock price decline. The company also addressed issues related to its annual meeting and entered into an Equity Purchase Agreement with Square Gate.

Specific data regarding demand seasonality for Artelo Biosciences, Inc.'s products and services is not available. As a clinical-stage biopharmaceutical company, its revenue generation is primarily tied to drug development milestones and potential future commercialization, rather than seasonal consumer demand.

Artelo Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics that target lipid-signaling pathways, including the endocannabinoid system. Its product candidate pipeline includes ART27.13 for anorexia in cancer patients, ART12.11 for anxiety and related disorders, ART26.12 for neuropathy and other conditions, and ART-002 for obesity and metabolic disorders.

Artelo Biosciences, Inc. is based in Solana Beach, California, and develops and commercializes its therapeutics in the United States.

Artelo Biosciences' brand reputation has been influenced by its clinical progress and financial challenges. Analyst ratings generally suggest a "Neutral" or "Hold" consensus. Concerns have been raised regarding a "perplexing strategy related to a crypto initiative," which has led to short-term uncertainty and dilution concerns. The company's struggle to maintain Nasdaq listing standards has also impacted its standing.

As of January 2026, institutional investors hold 1.64% of Artelo Biosciences' shares, while insiders hold 10.64%. Overall, institutions hold 4.09% of the shares outstanding. Major institutional owners include DRW Securities, LLC, Vanguard Group Inc, Morgan Stanley, Citigroup Inc, UBS Group AG, Fmr Llc, Bank Of America Corp /de/, Rothschild Investment Llc, and Royal Bank Of Canada.